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Patients treated with cancer chemotherapy are at 
risk of infertility. Gametogenesis is highly regulated 
process and many physical, chemical and environmental 
factors can affect the final quality and quantity of 
gametes. Oogenesis in particular is more prone to such 
factors; being started early in intrauterine life, the 
process of ovum production will conclude only after 
fertilization. During this long journey the follicles will 
pass through primordial, primary and secondary stages 
before it becomes mature Graafian follicle and 
eventually to environmental factors may have higher 
chances of disrupting the process. During the formation 
of ovum, the dividing oocyte will halt at two specific 
steps, one at prophase of first meiosis and second arrest 
at metaphase of second meiosis. This peculiar aspect of 
oogenesis makes the process vulnerable for many 
disruptive environmental factors.  
Gemcitabine, a fluorinated nucleoside 
antimetabolite drug, used for treatment of cancers of 
pancreas, breast, bladder and lung will also have adverse 
effects on fertility as they have detrimental action on 
gonads1. Novel approaches in early detection and 
effective chemotherapeutic drugs have increased the 
survival rate of these patients, issue of fertility is of 
significance post treatment2,3.Mechanisms of ovarian 
toxicity differ with the anticancer drugs. It may involve 
loss of ovarian reserve. Alkylating agents accelerated the 
apoptosis of primordial follicles in both animal model 
and in preclinical studies4. Doxorubicin, an anthracycline 
antimetabolite can cross the blood-follicle barrier and 
induce apoptosis of oocyte5. Several studies have 
documented signs of fibrosis in the cortical stroma, and 
changes in the capillaries were observed in ovaries 
exposed to chemotherapy6,7.Oxidative stress may also 
play a role in gonadotoxicity from some of the 
chemotherapeutic agents like cyclophosphamide3.It has 
been shown that gemcitabine has adverse effects on 
spermatogenesis in mice 
model8.Fluoropyrimidines being the backbone of 
chemotherapy in many cancers, act on S – phase of cell 
cycle. Clinical data regarding its impact on fertility is 
limited. 5-Fluorouracil may result in premature ovarian 
failure9.A study performed on a mouse model shed light 
on a possible correlation between a potential toxic effect 
of 5-FU to ovarian function and a circadian timing of 
administration of the agent
10
. The evidence for a 
potential gonadotoxic effect of Imatinib mesylate is 
proven in mice11. A study on leukemic mouse model 
ABSTRACT 
Background and objectives:Advances in cancer chemotherapy have led to improved survival rates and poses greater 
emphasis on preserving quality of life post-treatment. Gonadotoxicity is a well-recognized side effect of many cancer 
chemotherapeutic agents. This study was designed to evaluate the effects of gemcitabine, an antimetabolite anticancer drug, on 
oogenesis in Swiss albino mice and its reversibility. 
Methods:Thirty six inbred female Swiss albino mice in diestrous phase were selected and divided into three groups of twelve 
each. Groups were labelled as A, B and Control. Groups A and B received 40 mg/kg and 80 mg/kg of gemcitabine 
intraperitoneally. The control group received saline intraperitoneally. At the end of two weeks 6 mice were sacrificed from 
each group and the rest at the end of 2 months.  Ovaries were studied histologically.  
Results: After 2 weeks, the ovaries of experimental group mice showed more number of atretic follicles as compared to 
control group (p<0.01). The diameter of corpus lutea was more, though a reduction in number was recorded in experimental 
group (p<0.05).  Whereas after 2 months, both the experimental groups showed no difference in terms of atretic follicles, 
diameter and number of corpus lutea (p>0.05). 
Conclusions:These findings suggest that administration of gemcitabine may have profound effects on oogenesis and hence 
female fertility. This study also suggests that the effects are reversible.  
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using therapeutic doses of Imatinib reports no effects on 
folliculogenesis or spermatogenesis12. Similarly many 
anticancer drugs including vinca alkaloids have shown 
no effects on follicles13. 
Since many anticancer drugs have differential 
effects on ovarian functions, this study was designed to 
evaluate the effects of gemcitabine on oogenesis. 
Gemcitabine usually administered as single dose in 
treatment of cancers. The current study was designed to 
simulate the blood levels of therapeutic dose of 
gemcitabine in mice model.Few studies have done 
studies on effects of gemcitabine on ovaries8. Its 
reversibility hasn’t been evaluated.  
MATERIALS AND METHODS 
The experiment was conducted on 50 day old 
Swiss albino mice, weighing 20 – 25 grams. Mice were 
fed on standard feed and hosted in a 12 hour night day 
cycle environment and allowed water ad libitum. 
Optimum temperatures maintained throughout the 
experiment. The procedures and the handling of the mice 
were reviewed and approved by the Institutional Animal 
Care and Use committee. All mice received humane care 
in compliance with the CPCSEA.  
Drug: Gemcitabine (Gemita lyophilized, Fresenius Kabi 
Oncology Ltd.) was dissolved in sterile water and 
intraperitoneally injected into mice using insulin 
syringes. The whole reconstituted drug was used for the 
study at once, within 24 hours, in order to maintain the 
potency of the reconstituted drug. Any unused 
reconstituted drug is discarded. 
Study design: Around 60 inbred female Swiss albino 
mice were screened. Total thirty sixmice in diestrous 
phase were selected and divided into 3 groups of twelve 
each. Diestrous phase was determined by vaginal smear 
cytology. Groups were labelled control, A and B groups. 
Experimental groups i.e. A and B were given 40 mg/kg 
and 80 mg/kg of gemcitabine intraperitoneally 
respectively. Control mice were normal saline 
intraperitoneally once. After two weeks, that’s at 14th day 
after last intraperitoneal injection, half of the mice (n=6) 
from each group were sacrificed by sodium pentobarbital 
injection and ovaries were dissected out and studied. 
Rest of the mice were sacrificed after 2 months and their 
ovaries were studied similarly. Gross features of ovaries 
and vascularity were noted at the time of dissection.  
Histology: Mice ovaries are stored in Bouins’ solution 
for 24 hours for fixation, processed and paraffin 
embedded. 5 µ serial sections were taken and stained by 
standard hematoxylin and eosin. 
Ovarian sections and classification of ovarian follicles: 
Follicle types in ovarian crosssectionswere defined as 
followed: Primordialfollicles comprised an 
oocytesurrounded by a single layer of cuboidalgranulosa 
cells. Primary follicles comprisedan oocyte surrounded 
by two ormore layers of granulosa cells with noantrum. 
Secondary follicles were distinguishedby an antrum 
within the granulosacell layers enclosing the oocyte. 
Atretic follicles were those displaying twoor more of the 
following criteria within asingle cross-section: more than 
twopyknotic nuclei, granulosa cells within theantral 
cavity, granulosa cells pulling awayfrom the basement 
membrane, and/oruneven layers of granulosa 
cells.Follicles without oocyte with degenerative or with 
no definitive granulosa cells and theca cells are 
considered as atretic follicles. Follicles without definitive 
oocyte with regularly arranged granulosa and theca 
(internal and external) cells are not considered for count 
of atretic follicles and their count was considered in 
subsequent serial sections. Estimation of number of 
follicles per ovary was made by 
incorporatingstereological sampling protocols ona 
predetermined fraction of ovarian serial sections. In 
present study, every 6th, 10th and 14th sections were used. 
Follicles (withvisible nuclei) were counted if they 
appearedin one section but not the consecutive"look up" 
section, which ensured thatfollicles were counted only 
once. 
The slides prepared were observed under the 
morphometric microscope and analysed using Jenoptik 
Optical Systems Digital morphometry microscope, 
Business Unit Digital Imaging, Goeschwitser Str. 25, 
07745 Jena, Germany. Software used: ProgRes® Capture 
Pro 2.7 release 003. The size in terms of diameter, 
circumference and area of corpus lutea were measured.  
Statistical analysis: All data observed were expressed as 
Mean ± SD (standard deviation) and statistical 
significance of the histomorphometric data observed was 
performed by one-way ANOVA and Student 't' test 
(p<0.05 was accepted as  statistically significant).   
RESULTS:  
Gross morphology 
There was significant weight loss of ovary in A 
and B group both after 2 weeks in comparison to control 
group (table 1). The weights of ovaries in A and B 
groups were comparable and no statistical difference 
with control group after 2 months. There was decreased 
visible vascularity of the surface of ovaries after 2 
weeks. 
The ovarian histomorphometry 
Control group mice showed normal architecture of 
primordial and primary follicles, Graafian follicles at 
various stages of development (Fig. 1). Ovaries of mice 
treated with gemcitabine showed significant decrease in 
number of primary and Graafian follicles(p<0.05) (Fig. 
2). After 2 weeks of administration of gemcitabine, the 
ovaries showed significantly more atretic folliclesas 
compared to control group (p< 0.01). There was no 
change in diameter, circumference and area of Graafian 
follicles in experimental mice in comparison to control 
group at end of 2 weeks (p=0.8). There was significant 
decrease in number, diameter, circumference and area of 
corpus luteum in ovaries of experimental mice with 
respect to control group (p<0.05).   
After 2 months there was no significant 
difference between experimental group and control 
groups with respect to number of atretic and Graafian 
follicles. The difference in sizes of corpus lutea of 
experimental and control group had not differed 
significantly after 2 months of administration of drug 
(table 2). 
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Table 1: Tabulation of weight of ovary, number of primordial, primary, secondary, Graafian, atretic follicles and corpus 
luteum with its size in mice treated withintraperitomeal gemcitabine for 7 days and sacrificed after 2 weeks. Each 
group n=6. Data represented as Mean ± standard deviation.* p<0.05 between Group A and control and group B and 
control. 
At the end of 2
nd
 week Group A Group B Control 
Ovary weight (mg) 2.84 ± 0.38* 2.4 ± 0.44* 3.58 ± 0.8 
Number of follicles 
Primordial  14.91 ± 3.67* 12.56 ± 1.25* 30.45 ± 2.24 
Primary  8.72 ± 3.23* 7.45 ± 0.95* 12.54 ± 3.42 
Secondary 2.11 ± 1.13* 1.45 ± 1.54* 6.42 ± 2.12 
Graafian 1.52 ± 0.79* 1.85 ± 0.92* 2.52 ± 1.46 
Atretic 2.33 ± 1.36* 3.05 ± 0.88* 1.54 ± 0.55 
Corpus luteum 1.61 ± 0.81* 1.75 ± 0.56* 2.57 ± 1.02 
Size 
Diameter (µ) 334.11 ± 52.49* 298.12 ± 45.40* 424.26 ± 56.80 
Circumference (µ) 1050.06 ± 164.96* 1205.7 ± 144.24* 1460.48 ± 158.56 
Area (sq.µ) 359.73 ± 108.19* 398.36 ± 100.18* 454.25 ± 121.26 
 
Table 2: Tabulation of weight of ovary, number of primordial, primary, secondary, Graafian, atretic follicles and corpus 
luteum with its size in mice treated with intraperitoneal gemcitabine for 7 days and sacrificed after 2 months. Each 
group n=6. Data represented as Mean ± standard deviation.P >0.05 between group A and control, group B and control. 
 
Group A Group B Control 
Ovary weight (mg) 3.86 ± 0.44 3.58 ± 0.26 3.66 ± 0.2 
Number of follicles 
  Primordial  33.63 ± 2.55 30.42 ± 0.56 32.24 ± 2.42 
primary  12.89 ± 3.12 13.52 ± 1.20 12.62 ± 3.24 
Secondary 4.98 ± 1.45 5.2 ± 0.95 5.95 ± 1.21 
Graafian 2.73 ± 0.85 2.86 ± 0.42 2.65 ± 0.54 
Atretic 1.62 ± 1.22 1.85 ± 0.75 1.58 ± 0.5 
corpus luteum 2.05 ± 0.65 1.2 ± 0.85 2.95 ± 0.65 
Size 
   diameter (micron) 386.5 ± 17.85 405.65 ± 42.56 412.4 ± 45.62 
circumference (micron) 1180.48 ± 108.32 1286.92 ± 112.48 1265.45 ± 142.22 
area (sq. micro) 364.48 ± 65.58 400.58 ± 88.9 425.65 ± 124.25 
 
 
Figure 1: Normal architecture of control mice. H & E stain. 
10X. PrF - Primordial follicle, PF - Primary follicle, SF – 
Secondary follicle, AF – Atretic follicle, GF – Graafian follicle. 
 
Figure 2: Histological changes in ovaries of group A mice after 
intraperitoneal gemcitabine injections. H & E stain. 10X. PrF - 
Primordial follicle, PF - Primary follicle, SF – Secondary 
follicle, AF – Atretic follicle, GF – Graafian follicle.
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DISCUSSION:  
Gemcitabine is an antimetabolite anticancer drug, used 
predominantly in chemotherapy of cancers of breast, 
pancreatic tumors and non-small cell lung carcinoma. 
Being a nucleoside analog it will interfere with DNA 
replication in actively dividing cells. Ovaries have got 
effective proactive and prosurvival mechanism for 
protection of germ cells. In this study it is attempted to 
explore the effects of disruptive agents like 
chemotherapeutic drugs on the ovarian architecture using 
gemcitabine.  
It has been conclusively established in this study that 
gemcitabine disrupts the process of oogenesis. 
Gemcitabine administration has resulted in of increase in 
number of atretic follicles, decrease in number of 
primary follicles and decrease in size of corpus lutea. 
Similar results using Imatinib mesylate in rats’ ovaries 
has been reported. Loss of oocyte in many of the follicles 
appreciated in present study may be due to initiation of 
oxidative stress and chromosomal obliteration. Similar 
oocyte toxic effects are reported in animal studies using 
doxorubicin5 and platinum based compounds14. 
Studies using other antimetabolite chemotherapeutic 
agents in animal models reinforce the present results. 
Toxic effects of 5-Fluorouracil have been shown in mice 
model and it has been proved that it brings phase 
dependent changes in ovarian functions15. Clinical data 
of the effects of antimetabolite agents on ovarian 
functions and intern fertility is very limited. Therefore 
the present study using mice model is of significance in 
proving the detrimental effects of gemcitabine on 
oogenesis.  
In the present study it was noted that the size of corpus 
luteum were reduced after 2 weeks of administration of 
drug. This is in contrast to a similar study using Imatinib 
on mice where an increase in corpus luteum size is 
reported12. Differential timing in administration of drug 
with respect to estrous cycle may explain differential 
effects brought by these gonadotoxic agents. Present 
study conclusively proves that the ovarian toxic effects 
will fade off and most of detrimental effects are 
reversible after 2 months of administration of insulting 
agent. Such reversibility in animal model is not reported 
in literature so far to the best of our knowledge. This was 
evident by near normal appreciation of ovarian 
architecture histologically with no significant difference 
in number of primordial, primary, Graafian and atretic 
follicles in ovaries of experimental animals and in 
control group. The size of corpus lutea in experimental 
and control group did not differ significantly. We 
conclude that the effects of gemcitabine are reversible 
after 2 months at least with respect to histological 
architecture in animal model.  
Limitations: Present study is designed to evaluate 
histological effects only. This study has not shown light 
on ovarian functions which can be analysed through 
estimation of hormones in blood.  
Merits: This study evaluates the reversibility of effects 
of gemcitabine after its acute effects fades off. The 
results will have crucial implications when the drug is 
administered to young females.  
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